A Grey

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. Grey A, Bolland M. Web of industry, advocacy, and academia in the management of osteoporosis. BMJ. 2015;351:h3170 pubmed publisher
  2. Wang M, Grey A, Bolland M. Conflicts of interest and expertise of independent commenters in news stories about medical research. CMAJ. 2017;189:E553-E559 pubmed publisher
    ..Academic or financial conflicts of interest were frequently present among independent commenters but infrequently reported, and were often associated with the disposition of comments about the source research. ..
  3. request reprint
    Grey A, Chen Q, Xu X, Callon K, Cornish J. Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology. 2003;144:4886-93 pubmed
    ..These data suggest that IGF-I signals osteoblast mitogenesis and survival through parallel, partly overlapping intracellular pathways involving PI-3 kinase, p42/44 MAPKs, and G beta gamma subunits. ..
  4. request reprint
    Grey A, Banovic T, Zhu Q, Watson M, Callon K, Palmano K, et al. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol. 2004;18:2268-78 pubmed
    ....
  5. request reprint
    Grey A, Zhu Q, Watson M, Callon K, Cornish J. Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. Mol Cell Endocrinol. 2006;251:96-102 pubmed
    ....
  6. Grey A, Bolland M, Horne A, Mihov B, Gamble G, Reid I. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. CMAJ. 2017;189:E1130-E1136 pubmed publisher
    ..Clinical trials would be justified to evaluate the effects on fracture risk of less frequent or lower doses of zoledronate than are currently recommended. www.anzctr.org.au, no. ACTRN12607000576426. ..

Locale

Collaborators

Detail Information

Publications6

  1. Grey A, Bolland M. Web of industry, advocacy, and academia in the management of osteoporosis. BMJ. 2015;351:h3170 pubmed publisher
  2. Wang M, Grey A, Bolland M. Conflicts of interest and expertise of independent commenters in news stories about medical research. CMAJ. 2017;189:E553-E559 pubmed publisher
    ..Academic or financial conflicts of interest were frequently present among independent commenters but infrequently reported, and were often associated with the disposition of comments about the source research. ..
  3. request reprint
    Grey A, Chen Q, Xu X, Callon K, Cornish J. Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology. 2003;144:4886-93 pubmed
    ..These data suggest that IGF-I signals osteoblast mitogenesis and survival through parallel, partly overlapping intracellular pathways involving PI-3 kinase, p42/44 MAPKs, and G beta gamma subunits. ..
  4. request reprint
    Grey A, Banovic T, Zhu Q, Watson M, Callon K, Palmano K, et al. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol. 2004;18:2268-78 pubmed
    ....
  5. request reprint
    Grey A, Zhu Q, Watson M, Callon K, Cornish J. Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. Mol Cell Endocrinol. 2006;251:96-102 pubmed
    ....
  6. Grey A, Bolland M, Horne A, Mihov B, Gamble G, Reid I. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. CMAJ. 2017;189:E1130-E1136 pubmed publisher
    ..Clinical trials would be justified to evaluate the effects on fracture risk of less frequent or lower doses of zoledronate than are currently recommended. www.anzctr.org.au, no. ACTRN12607000576426. ..